Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CVM advanced for three days, in 250 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on June 17, 2022. You may want to consider a long position or call options on CVM as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
CVM moved above its 50-day moving average on May 27, 2022 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CVM crossed bullishly above the 50-day moving average on June 03, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 193 cases where CVM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CVM broke above its upper Bollinger Band on June 22, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CVM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.792) is normal, around the industry mean (24.800). P/E Ratio (0.000) is within average values for comparable stocks, (94.818). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.614). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (290.018).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of immunotherapy products for the treatment of cancer and infectious diseases
A.I.dvisor indicates that over the last year, CVM has been loosely correlated with EXEL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then EXEL could also see price increases.
|EXEL - CVM|
|KALV - CVM|
|GTHX - CVM|
|VCYT - CVM|
|ALT - CVM|